Home/Filings/4/0000914190-09-000235
4//SEC Filing

CARDIOVASCULAR SYSTEMS INC 4

Accession 0000914190-09-000235

CIK 0001222929operating

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 7:00 PM ET

Size

42.8 KB

Accession

0000914190-09-000235

Insider Transaction Report

Form 4
Period: 2009-02-25
Transactions
  • Conversion

    Common Stock

    2009-02-25+132,042283,209 total(indirect: By LLC)
  • Conversion

    Common Stock

    2009-02-25+54,585381,029 total(indirect: By LLC)
  • Disposition to Issuer

    Common Stock

    2009-02-2560,0000 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2009-02-2510,0000 total
    Common Stock (10,000 underlying)
  • Disposition to Issuer

    Warrant

    2009-02-2583,3330 total(indirect: By LLC)
    Common Stock (83,333 underlying)
  • Disposition to Issuer

    Warrant

    2009-02-2587,4160 total(indirect: By LLC)
    Common Stock (87,416 underlying)
  • Conversion

    Common Stock

    2009-02-25+43,235326,444 total(indirect: By LLC)
  • Disposition to Issuer

    Common Stock

    2009-02-25381,0290 total(indirect: By LLC)
  • Disposition to Issuer

    Stock Option (right to buy)

    2009-02-2523,3190 total
    Common Stock (23,319 underlying)
  • Conversion

    Series A-1 Conv Preferred Stock

    2009-02-2543,2350 total(indirect: By LLC)
    Common Stock (43,235 underlying)
  • Conversion

    Warrant

    2009-02-2518,7500 total(indirect: By LLC)
    From: 2006-07-19Exp: 2011-07-19Series A Conv Preferred Stock (18,750 underlying)
  • Conversion

    Warrant

    2009-02-25+18,75018,750 total(indirect: By LLC)
    From: 2006-07-19Exp: 2011-07-19Common Stock (18,750 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2009-02-2515,0000 total
    Common Stock (15,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2009-02-2520,0000 total
    Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2009-02-256,6810 total
    Common Stock (6,681 underlying)
  • Conversion

    Series A Conv Preferred Stock

    2009-02-25132,0420 total(indirect: By LLC)
    Common Stock (132,042 underlying)
  • Conversion

    Series B Conv Preferred Stock

    2009-02-2554,5850 total(indirect: By LLC)
    Common Stock (54,585 underlying)
  • Disposition to Issuer

    Warrant

    2009-02-2518,7500 total(indirect: By LLC)
    Common Stock (18,750 underlying)
Footnotes (11)
  • [F1]Immediately prior to the consummation of the merger between the issuer and Replidyne, Inc., each share of Series A convertible preferred stock was converted into approximately 1.005 shares of the issuer's common stock.
  • [F10]Immediately prior to the consummation of the merger between the issuer and Replidyne, Inc., each Series A convertible preferred stock warrant was converted into a warrant to purchase the issuer's common stock; each Series A convertible preferred share covered by the warrants was converted into approximately 1.005 shares of the issuer's common stock and the exercise price of each warrant was adjusted by multiplying the number of Series A shares covered by the warrant by the warrant exercise price, and dividing by the total number of the issuer's common shares subject to the converted Series A warrant.
  • [F11]Disposed of pursuant to a merger agreement among the issuer, Responder Merger Sub, Inc. and Replidyne, Inc. (now known as "Cardiovascular Systems, Inc."), pursuant to which each of the issuer's common stock warrants was assumed by Replidyne, Inc. and became exercisable to purchase shares of Replidyne, Inc. common stock; each share covered by the issuer's common stock warrants was converted into 0.647 shares of common stock of Replidyne, Inc., and the exercise price of each warrant was adjusted by dividing the pre-merger exercise price by 0.647 and rounding up to the nearest cent.
  • [F2]Shares are held by GDN Holdings, LLC, of which Dr. Nelson is the sole owner.
  • [F3]Immediately prior to the consummation of the merger between the issuer and Replidyne, Inc., each share of Series A-1 convertible preferred stock was converted into approximately 1.032 shares of the issuer's common stock.
  • [F4]Immediately prior to the consummation of the merger between the issuer and Replidyne, Inc., each share of Series B convertible preferred stock was converted into approximately 1.010 shares of the issuer's common stock.
  • [F5]Disposed of pursuant to a merger agreement among the issuer, Responder Merger Sub, Inc. and Replidyne, Inc. (now known as "Cardiovascular Systems, Inc."), pursuant to which each share of the issuer's common stock was converted into 0.647 shares of common stock of Replidyne, Inc.
  • [F6]Disposed of pursuant to a merger agreement among the issuer, Responder Merger Sub, Inc. and Replidyne, Inc. (now known as "Cardiovascular Systems, Inc."), pursuant to which each of the issuer's stock options was assumed by Replidyne, Inc. and became exercisable to purchase shares of Replidyne, Inc. common stock; each share covered by the issuer's options was converted into 0.647 shares of common stock of Replidyne, Inc., and the exercise price of each option was adjusted by dividing the pre-merger exercise price by 0.647 and rounding up to the nearest cent.
  • [F7]Each share of Series A convertible preferred stock was convertible at any time, at the holder's election, into 1.005 shares of common stock and had no expiration date.
  • [F8]Each share of Series A-1 convertible preferred stock was convertible at any time, at the holder's election, into 1.032 shares of common stock and had no expiration date.
  • [F9]Each share of Series B convertible preferred stock was convertible at any time, at the holder's election, into 1.010 shares of common stock and had no expiration date.

Issuer

CARDIOVASCULAR SYSTEMS INC

CIK 0001222929

Entity typeoperating
IncorporatedMN

Related Parties

1
  • filerCIK 0001222929

Filing Metadata

Form type
4
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 7:00 PM ET
Size
42.8 KB